Cargando…

Sclerostin is upregulated in the early stage of chondrogenic differentiation, but not required in endochondral ossification in vitro

Sclerostin is a potent inhibitor of the canonical Wnt signaling pathway. Wnt signaling pathways have multiple roles in the regulation of cartilage development, growth, and maintenance. This study focused on the role of sclerostin in the process of chondrogenic differentiation. We hypothesized that s...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Yasuteru, Kumagai, Ken, Imai, Sosuke, Miyatake, Kazuma, Saito, Tomoyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072128/
https://www.ncbi.nlm.nih.gov/pubmed/30071108
http://dx.doi.org/10.1371/journal.pone.0201839
_version_ 1783343975878361088
author Yamaguchi, Yasuteru
Kumagai, Ken
Imai, Sosuke
Miyatake, Kazuma
Saito, Tomoyuki
author_facet Yamaguchi, Yasuteru
Kumagai, Ken
Imai, Sosuke
Miyatake, Kazuma
Saito, Tomoyuki
author_sort Yamaguchi, Yasuteru
collection PubMed
description Sclerostin is a potent inhibitor of the canonical Wnt signaling pathway. Wnt signaling pathways have multiple roles in the regulation of cartilage development, growth, and maintenance. This study focused on the role of sclerostin in the process of chondrogenic differentiation. We hypothesized that sclerostin is essential to induce chondrogenic differentiation and regulate endochondral ossification. ATDC5 cells were used to investigate chondrogenic differentiation and terminal calcification. During chondrogenic differentiation, intrinsic sclerostin was upregulated in the early stage, but downregulated in the late stage. Addition of sclerostin elevated expressions of Sox9 and Col2a1 (P<0.05) and reduced expressions of Runx2, Col10a1, MMP-3, MMP-13, and ADAMTS5 (P<0.05) through inhibition of the Wnt-β-catenin signaling pathway (P<0.05). Terminal calcification was significantly inhibited by sclerostin (P<0.05). In contrast, deletion of sclerostin decreased expressions of Sox9 and Col2a1 (P<0.05), increased expressions of Runx2, Col10a1, MMP-3, and MMP-13 (P<0.05), and promoted terminal calcification (P<0.05). This study provides insights into the possible role of sclerostin in the regulation of chondrogenic differentiation. Sclerostin is upregulated in the early stage of chondrogenic differentiation, but is not required in endochondral ossification. Sclerostin is a candidate modulator for chondrogenic differentiation.
format Online
Article
Text
id pubmed-6072128
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-60721282018-08-16 Sclerostin is upregulated in the early stage of chondrogenic differentiation, but not required in endochondral ossification in vitro Yamaguchi, Yasuteru Kumagai, Ken Imai, Sosuke Miyatake, Kazuma Saito, Tomoyuki PLoS One Research Article Sclerostin is a potent inhibitor of the canonical Wnt signaling pathway. Wnt signaling pathways have multiple roles in the regulation of cartilage development, growth, and maintenance. This study focused on the role of sclerostin in the process of chondrogenic differentiation. We hypothesized that sclerostin is essential to induce chondrogenic differentiation and regulate endochondral ossification. ATDC5 cells were used to investigate chondrogenic differentiation and terminal calcification. During chondrogenic differentiation, intrinsic sclerostin was upregulated in the early stage, but downregulated in the late stage. Addition of sclerostin elevated expressions of Sox9 and Col2a1 (P<0.05) and reduced expressions of Runx2, Col10a1, MMP-3, MMP-13, and ADAMTS5 (P<0.05) through inhibition of the Wnt-β-catenin signaling pathway (P<0.05). Terminal calcification was significantly inhibited by sclerostin (P<0.05). In contrast, deletion of sclerostin decreased expressions of Sox9 and Col2a1 (P<0.05), increased expressions of Runx2, Col10a1, MMP-3, and MMP-13 (P<0.05), and promoted terminal calcification (P<0.05). This study provides insights into the possible role of sclerostin in the regulation of chondrogenic differentiation. Sclerostin is upregulated in the early stage of chondrogenic differentiation, but is not required in endochondral ossification. Sclerostin is a candidate modulator for chondrogenic differentiation. Public Library of Science 2018-08-02 /pmc/articles/PMC6072128/ /pubmed/30071108 http://dx.doi.org/10.1371/journal.pone.0201839 Text en © 2018 Yamaguchi et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Yamaguchi, Yasuteru
Kumagai, Ken
Imai, Sosuke
Miyatake, Kazuma
Saito, Tomoyuki
Sclerostin is upregulated in the early stage of chondrogenic differentiation, but not required in endochondral ossification in vitro
title Sclerostin is upregulated in the early stage of chondrogenic differentiation, but not required in endochondral ossification in vitro
title_full Sclerostin is upregulated in the early stage of chondrogenic differentiation, but not required in endochondral ossification in vitro
title_fullStr Sclerostin is upregulated in the early stage of chondrogenic differentiation, but not required in endochondral ossification in vitro
title_full_unstemmed Sclerostin is upregulated in the early stage of chondrogenic differentiation, but not required in endochondral ossification in vitro
title_short Sclerostin is upregulated in the early stage of chondrogenic differentiation, but not required in endochondral ossification in vitro
title_sort sclerostin is upregulated in the early stage of chondrogenic differentiation, but not required in endochondral ossification in vitro
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072128/
https://www.ncbi.nlm.nih.gov/pubmed/30071108
http://dx.doi.org/10.1371/journal.pone.0201839
work_keys_str_mv AT yamaguchiyasuteru sclerostinisupregulatedintheearlystageofchondrogenicdifferentiationbutnotrequiredinendochondralossificationinvitro
AT kumagaiken sclerostinisupregulatedintheearlystageofchondrogenicdifferentiationbutnotrequiredinendochondralossificationinvitro
AT imaisosuke sclerostinisupregulatedintheearlystageofchondrogenicdifferentiationbutnotrequiredinendochondralossificationinvitro
AT miyatakekazuma sclerostinisupregulatedintheearlystageofchondrogenicdifferentiationbutnotrequiredinendochondralossificationinvitro
AT saitotomoyuki sclerostinisupregulatedintheearlystageofchondrogenicdifferentiationbutnotrequiredinendochondralossificationinvitro